** Hong Kong-listed shares of RemeGen Co 9995.HK rise 5.3% to HK$84.65, their highest point since December 2021, and on course for second session of gains

** Shanghai-listed stock 688331.SS climbs 5.6% to 83.93 yuan, their highest level since February 2023

** RemeGen says it has granted Santen Pharmaceutical Co's 4536.T unit Santen Pharmaceutical (China) the exclusive rights to develop, manufacture and commercialize the company's RC28-E Injection in Greater China, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia and Malaysia

** Company shall receive from Santen China an upfront payment of 250 million yuan ($34.79 million), development and regulatory milestone payments of up to 520 million yuan, and sales milestone payments of up to 525 million yuan

** RemeGen says it will also receive tiered sales royalties ranging from high single-digit to double-digit percentages based on product sales within the licensed territories

** RemeGen's developed RC28-E Injection is a drug for ocular neovascular diseases

** YTD, Hong Kong stock up 483.3%, Shanghai shares up 172.7%

($1 = 7.1858 Chinese yuan)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))